Andrew J. Rettenmaier, PhD | Authors

Healthcare Financing and the Cost of Cancer Care

October 23, 2012

Controlling healthcare spending has been, and appears destined to remain, at the center of the public policy debate at each level of government, given that much of the healthcare bill is paid by taxpayers.

Examining the Geography of Cancer Incidence and Care

November 15, 2011

The article by Aneja, Gross, Soulos, and Yu outlines applications of geographical information systems (GIS) software to oncology research.

Comparative Effectiveness and Comparative Costs

May 15, 2010

Kilbridge correctly points out that comparative effectiveness research (CER) does not require cost data. It should also be pointed out, however, that the composition of the quality-adjusted life-year (QALY) gain of one intervention over another-whether the QALY gain is achieved mainly in the dimension of longevity or in the dimension of quality of life-has real consequences in terms of comparative costs of the interventions. Basically, a longevity increase entails additional consumption costs and additional labor earnings, essentially negative costs, during the extended life that should be included in the “cost” of an intervention.[1-3] Because labor earnings tend to be negligible relative to consumption costs toward the end of one’s life, due to sickness or retirement, failure to incorporate consumption costs and labor earnings into the comparative costs of two interventions generates a bias in favor of the intervention with the larger longevity effect.